AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14563793 — intervention group
Group type: COMPARATOR
Intervention: Perforated cloth tape
Number of subjects: 99
Study 10998876 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA using a disposable PCA device (3.0 ml type)
Number of subjects: 22
Study 10998876 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural group with epidural fentanyl (15 micrograms.ml‐1) and bupivacaine (1.25 mg.ml‐1)
Number of subjects: 22
Study 10998876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 8698952 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session cognitive-behavioral therapy (CB)
Number of subjects: 117
Study 8698952 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-session cognitive-behavioral therapy (CB)
Number of subjects: 117
Study 8698952 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session psychodynamic-interpersonal therapy (PI)
Number of subjects: 117
Study 8698952 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-session psychodynamic-interpersonal therapy (PI)
Number of subjects: 117
Study 8698952 — intervention group
Group type: COMPARATOR
Intervention: psychodynamic-interpersonal therapy (PI)
Number of subjects: 117
Study 8698952 — intervention group
Group type: COMPARATOR
Intervention: cognitive-behavioral therapy (CB)
Number of subjects: 117
Study 8698952 — intervention group
Group type: COMPARATOR
Intervention: 8-session treatments
Number of subjects: 117
Study 8698952 — intervention group
Group type: COMPARATOR
Intervention: 16-session treatments
Number of subjects: 117
Study 1427127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-D-fortified liquid milk
Number of subjects: 98
Study 1427127 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented milk
Number of subjects: 98
Study 1427127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk
Number of subjects: 98
Study 3892663 — intervention group
Group type: EXPERIMENTAL
Intervention: Padma 28
Number of subjects: 43
Study 3892663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31010876 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrecognized myocardial infarction (MI) detected by delayed‐enhancement MRI (DE‐MRI)
Number of subjects: 120
Study 31010876 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of unrecognized MI by DE‐MRI
Number of subjects: 120
Study 31010876 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrecognized MI by DE‐MRI
Number of subjects: 120
Study 31010876 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of unrecognized MI to clinical indices
Number of subjects: 120
Study 29897564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000 IU/d)
Number of subjects: 448
Study 29897564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study 26890560 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid early support (n = 9)
Number of subjects: 39
Study 26890560 — intervention group
Group type: COMPARATOR
Intervention: Medicaid late support (n = 9)
Number of subjects: 39
Study 26890560 — intervention group
Group type: COMPARATOR
Intervention: Non-Medicaid early support (n = 11)
Number of subjects: 39
Study 26890560 — intervention group
Group type: COMPARATOR
Intervention: Non-Medicaid late support (n = 10)
Number of subjects: 39
Study 26890560 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups with early support
Number of subjects: 39
Study 24071376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 46
Study 24071376 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 46
Study 22155435 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (BB) up-titration
Number of subjects: 219
Study 20422396 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medicines (ADMs) use
Number of subjects: 5145
Study 20422396 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression symptoms (BDI scores ≥ 11)
Number of subjects: 5145
Study 20422396 — intervention group
Group type: EXPERIMENTAL
Intervention: Both depression markers (elevated symptom scores and ADMs use)
Number of subjects: 5145
Study 20422396 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous BDI scores
Number of subjects: 5145
Study 20422396 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM use
Number of subjects: 5145
Study 17926164 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-informed protocol to protect and prevent body image concerns
Number of subjects: 23
Study 17926164 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image protection protocol
Number of subjects: 23
Study 16940738 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 mug
Number of subjects: 355
Study 16940738 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular syntometrine
Number of subjects: 355
Study 15491319 — intervention group
Group type: COMPARATOR
Intervention: Control protocol: rinsed twice daily for 1 min with 0.1% chlorhexidine (CHX) for 4 weeks.
Number of subjects: 60
Study 15491319 — intervention group
Group type: EXPERIMENTAL
Intervention: Test protocol: applied CHX locally using a very soft surgical toothbrush from days 3 to 14, and a soft toothbrush from days 14 to 28, twice daily, in addition to CHX rinsing.
Number of subjects: 60
Study 11307266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic vibration for 10 min (Groups 4, 5, 6)
Number of subjects: 84
Study 11307266 — intervention group
Group type: COMPARATOR
Intervention: No ultrasonic vibration (Groups 1, 2, 3)
Number of subjects: 84
Study 14655831 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram at a starting dose of 20 mg for 6 months
Number of subjects: 32
Study 14655831 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 32
Study 8306595 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-titrating insulin regimen
Number of subjects: 40
Study 8306595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-mixed insulin (30:70) delivered by disposable pen
Number of subjects: 40
Study 8306595 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin ratios other than 30:70
Number of subjects: 40
Study 8306595 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation on the pen for a further 12 months
Number of subjects: 40
Study 8306595 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for disposable pen and pre-mixed insulin regimen
Number of subjects: 40
Study 3525572 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide pneumatic tourniquet (12.5 cm) at low pressure
Number of subjects: 750
Study 3525572 — intervention group
Group type: COMPARATOR
Intervention: Conventional tourniquet (9 cm) at higher pressures
Number of subjects: 750
Study 30589994 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-774312 50 mg twice daily
Number of subjects: 0
Study 30589994 — intervention group
Group type: COMPARATOR
Intervention: ACT-774312 (single doses of 1-1000 mg or multiple doses of 30-500 mg)
Number of subjects: 0
Study 30589994 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-774312
Number of subjects: 0
Study 29522079 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-as-prevention intervention including monthly testing for HIV and rapid treatment initiation for those who became HIV-positive.
Number of subjects: 3337
Study 29522079 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly testing for HIV among HIV-negative individuals.
Number of subjects: 3337
Study 29522079 — intervention group
Group type: EXPERIMENTAL
Intervention: Linking participants to health care after the study.
Number of subjects: 3337
Study 26794930 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg/day)
Number of subjects: 108
Study 26794930 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg/day; 6-week cycles of 4 weeks on, 2 weeks off)
Number of subjects: 108
Study 26794930 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 108
Study 26794930 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 108
Study 24178792 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatabine (9-24 mg/d), administered orally 3 times a day for 3 months
Number of subjects: 146
Study 24178792 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered orally 3 times a day for 3 months
Number of subjects: 146
Study 24178792 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatabine
Number of subjects: 146
Study 22027848 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Balance® band
Number of subjects: 24
Study 22027848 — intervention group
Group type: COMPARATOR
Intervention: Placebo band
Number of subjects: 24
Study 22027848 — intervention group
Group type: COMPARATOR
Intervention: No band
Number of subjects: 24
Study 22027848 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance test conditions (EOFS, ECFS, EOFoS, ECFoS)
Number of subjects: 24
Study 19074154 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato-derived HES (6% HES 130/0.42), n=30
Number of subjects: 60
Study 19074154 — intervention group
Group type: COMPARATOR
Intervention: Maize-derived HES (6% HES 130/0.4), n=30
Number of subjects: 60
Study 19074154 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato-derived HES
Number of subjects: 60
Study 19074154 — intervention group
Group type: COMPARATOR
Intervention: Maize-derived HES
Number of subjects: 60
Study 17487260 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol in addition to ACE inhibitor
Number of subjects: 141
Study 17487260 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor without any beta-blocker (control)
Number of subjects: 141
Study 17487260 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 141
Study 15113451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (2 x 10(9) CFU/day)
Number of subjects: 11
Study 15113451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15113451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 11
Study 12351286 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9654256 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2a (3x10(6) IU, three times weekly for 18 months)
Number of subjects: 489
Study 9654256 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 489
Study 8270984 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-mg tamoxifen tablet taken once daily
Number of subjects: 30
Study 8270984 — intervention group
Group type: COMPARATOR
Intervention: 10-mg tamoxifen tablet taken twice daily
Number of subjects: 30
Study 2521930 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention program including physical and behavioral therapy
Number of subjects: 0
Study 2521930 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 31643025 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Talk intervention
Number of subjects: 172
Study 31643025 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study 30940108 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Action Programme (WAP)
Number of subjects: 330
Study 28030526 — intervention group
Group type: EXPERIMENTAL
Intervention: JE chimeric virus vaccine (JE-CV)
Number of subjects: 596
Study 28030526 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV booster vaccination
Number of subjects: 596
Study 25431482 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body MRI (WBMRI)
Number of subjects: 48
Study 23680389 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching TV
Number of subjects: 120
Study 23680389 — intervention group
Group type: COMPARATOR
Intervention: Motion-controlled gaming
Number of subjects: 120
Study 23680389 — intervention group
Group type: COMPARATOR
Intervention: Typical video games
Number of subjects: 120
Study 21868794 — intervention group
Group type: EXPERIMENTAL
Intervention: EZStep with NSAIDs (4-6 weeks)
Number of subjects: 198
Study 21868794 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs and physiotherapy (group 2A)
Number of subjects: 198
Study 21868794 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs, physiotherapy, and local steroid injection (group 2B)
Number of subjects: 198
Study 19108925 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan
Number of subjects: 0
Study 17889121 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cyclosporine (CyA) + sirolimus (SRL)
Number of subjects: 0
Study 17889121 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus (SRL) with cyclosporine (CyA) elimination at 3 months post-transplant
Number of subjects: 0
Study 15370683 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography in patients with achalasia
Number of subjects: 69
Study 15370683 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography in patients with neoplasms
Number of subjects: 69
Study 15370683 — intervention group
Group type: COMPARATOR
Intervention: Control group (sex‐ and age‐matched)
Number of subjects: 69
Study 15239872 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective change of intravenous cannulae every 48 hours
Number of subjects: 47
Study 15239872 — intervention group
Group type: COMPARATOR
Intervention: Control group (cannulae only removed if painful, dislodged, or signs of PVT)
Number of subjects: 47
Study 11122017 — intervention group
Group type: EXPERIMENTAL
Intervention: Liarozole 50 mg
Number of subjects: 139
Study 11122017 — intervention group
Group type: EXPERIMENTAL
Intervention: Liarozole 75 mg
Number of subjects: 139
Study 11122017 — intervention group
Group type: EXPERIMENTAL
Intervention: Liarozole 150 mg
Number of subjects: 139
Study 11122017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 9124990 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) administered as dropwise intravenous infusions in a single dose of 4/0.5 g 3 times a day for 5 to 17 days
Number of subjects: 40
Study 8249561 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tetracaine diluted in 1 ml of 10% glucose
Number of subjects: 45
Study 8249561 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tetracaine diluted in 2 ml of 10% glucose
Number of subjects: 45
Study 8249561 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tetracaine diluted in 4 ml of 10% glucose
Number of subjects: 45
Study 3524172 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine therapy (10 mg/kg/day)
Number of subjects: 20
Study 3524172 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine therapy
Number of subjects: 20
Study 29802630 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with keratinized mucosa (Group 1)
Number of subjects: 24
Study 29802630 — intervention group
Group type: COMPARATOR
Intervention: Implants without keratinized mucosa (Group 2)
Number of subjects: 24
Study 27203434 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg, monthly intravitreal injections for one year)
Number of subjects: 327
Study 27203434 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (0.5 mg, monthly intravitreal injections for one year)
Number of subjects: 327
Study 27203434 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 327
Study 27203434 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 327
Study 24225307 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental shuttle walk test (SWT)
Number of subjects: 19
Study 24225307 — intervention group
Group type: COMPARATOR
Intervention: 6-minute walk test (6MWT)
Number of subjects: 19
Study 22728576 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight hyaluronic acid (HA)
Number of subjects: 36
Study 22728576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20653757 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education
Number of subjects: 824
Study 20653757 — intervention group
Group type: COMPARATOR
Intervention: Control group (normative data)
Number of subjects: 824
Study 18541933 — intervention group
Group type: EXPERIMENTAL
Intervention: DOTS (thrice weekly for 2 months, followed by isoniazid and rifampicin thrice weekly for 4 months)
Number of subjects: 47
Study 18541933 — intervention group
Group type: COMPARATOR
Intervention: Daily tuberculosis chemotherapy (daily for 2 months, followed by isoniazid and rifampicin daily for 7 months)
Number of subjects: 47
Study 18541933 — intervention group
Group type: EXPERIMENTAL
Intervention: DOTS
Number of subjects: 47
Study 18541933 — intervention group
Group type: COMPARATOR
Intervention: Daily tuberculosis chemotherapy
Number of subjects: 47
Study 16822137 — intervention group
Group type: EXPERIMENTAL
Intervention: Original performance recordings
Number of subjects: 0
Study 16822137 — intervention group
Group type: COMPARATOR
Intervention: Tempo-transformed performance recordings
Number of subjects: 0
Study 12797567 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 ppm F‐ dentifrice
Number of subjects: 657
Study 12797567 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm F‐ dentifrice
Number of subjects: 657
Study 12797567 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 657
Study 12797567 — intervention group
Group type: COMPARATOR
Intervention: Placebo/1450 ppm F‐ dentifrice
Number of subjects: 657
Study 12797567 — intervention group
Group type: COMPARATOR
Intervention: Placebo/500 ppm F‐ dentifrice
Number of subjects: 657
Study 10235547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (3.2 microg/kg) in rabbits
Number of subjects: 0
Study 10235547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (4 mg/d) orally in NTG patients
Number of subjects: 0
Study 10235547 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle solution) in rabbits
Number of subjects: 0
Study 10235547 — intervention group
Group type: COMPARATOR
Intervention: Placebo in NTG patients
Number of subjects: 0
Study 8907805 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg daily for 12 weeks
Number of subjects: 31
Study 8907805 — intervention group
Group type: COMPARATOR
Intervention: Captopril 37.5 mg daily for 12 weeks
Number of subjects: 31
Study 8907805 — intervention group
Group type: COMPARATOR
Intervention: Indapamide and Captopril
Number of subjects: 31
Study 1905384 — intervention group
Group type: EXPERIMENTAL
Intervention: Various intervention strategies (re‐educative, persuasive, facilitative, power)
Number of subjects: 0
Study 1905384 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative methods to measure drug usage
Number of subjects: 0
Study 6342563 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT), consisting of weekly individual psychotherapy for six months
Number of subjects: 72
Study 6342563 — intervention group
Group type: COMPARATOR
Intervention: Low-contact treatment, consisting of one brief meeting per month for six months
Number of subjects: 72
Study 30935454 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27568682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary (Arabin® ASQ 65/25/32)
Number of subjects: 380
Study 27568682 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (no pessary)
Number of subjects: 380
Study 26422722 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 0
Study 26422722 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 0
Study 26422722 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 26422722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23725299 — intervention group
Group type: EXPERIMENTAL
Intervention: Evodial (Gambro, Lund, Sweden)
Number of subjects: 252
Study 23725299 — intervention group
Group type: COMPARATOR
Intervention: Standard care with saline flushes or blood predilution
Number of subjects: 252
Study 21840705 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate epidural analgesia
Number of subjects: 54
Study 21840705 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed epidural analgesia
Number of subjects: 54
Study 18627559 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF stretching group
Number of subjects: 62
Study 18627559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 17596770 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic training (60 min in warm water, three times a week for 12 weeks)
Number of subjects: 34
Study 17596770 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual leisure-time activities)
Number of subjects: 34
Study 15346948 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with polycomponent vaccine VP-4 (4 or 5 subcutaneous injections at an interval of 5-7 days)
Number of subjects: 75
Study 15346948 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving basic therapy
Number of subjects: 75
Study 12190996 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg three times a day for 2 days (six doses total)
Number of subjects: 8
Study 12190996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12190996 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 8
Study 9807740 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic cell therapy (AlloCT) with human recombinant interleukin 2 (rIL-2) for 3 days to activate donor PBL, followed by infusion of in vitro rIL-2 activated donor lymphocytes combined with 3-day rIL-2 therapy.
Number of subjects: 13
Study 9807740 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic cell therapy (AlloCT) with donor marrow cell infusion without further conditioning.
Number of subjects: 13
Study 7622801 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (24‐72 mg/day)
Number of subjects: 200
Study 7622801 — intervention group
Group type: COMPARATOR
Intervention: Trazodone (150‐450 mg/day)
Number of subjects: 200
Study 7622801 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 200
Study 7622801 — intervention group
Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 200
Study 2515716 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg
Number of subjects: 19
Study 2515716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19